Patient characteristics according to the WT1 and FLT3-ITD mutation status
| Characteristic . | WT1wt/FLT3-ITDneg . | WT1mut/FLT3-ITDneg . | WT1wt/FLT3-ITDpos . | WT1mut/FLT3-ITDpos . | P . |
|---|---|---|---|---|---|
| Sex, no. female/no. male | 178/185 | 23/14 | 104/67 | 22/19 | .05 |
| Type of AML, n* | .35 | ||||
| De novo | 288 | 29 | 146 | 33 | |
| s-AML | 43 | 3 | 10 | 2 | |
| t-AML | 9 | 0 | 3 | 0 | |
| Missing | 23 | 5 | 12 | 6 | |
| Median age, y (range) | 49.4 (16-60.9) | 41.9 (23-59.8) | 47.2 (18.3-60.9) | 46.4 (19.4-58.8) | .007 |
| Median WBC count, ×109/L (range) | 13.5 (0.2-369) | 13.9 (0.2-369) | 39.2 (0.2-345) | 30.1 (1.1-220) | .22 |
| Median PB blasts, % (range) | 27 (0-99) | 35 (0-98) | 55 (0-100) | 71 (1-96) | .01 |
| Median BM blasts, % (range) | 70 (0-100) | 72 (7-96) | 87 (2-100) | 88 (20-100) | .14 |
| Median LDH, U/L (range) | 362 (89-2371) | 422 (131-4566) | 559.5 (122-4091) | 755.5 (184-2992) | .007 |
| Characteristic . | WT1wt/FLT3-ITDneg . | WT1mut/FLT3-ITDneg . | WT1wt/FLT3-ITDpos . | WT1mut/FLT3-ITDpos . | P . |
|---|---|---|---|---|---|
| Sex, no. female/no. male | 178/185 | 23/14 | 104/67 | 22/19 | .05 |
| Type of AML, n* | .35 | ||||
| De novo | 288 | 29 | 146 | 33 | |
| s-AML | 43 | 3 | 10 | 2 | |
| t-AML | 9 | 0 | 3 | 0 | |
| Missing | 23 | 5 | 12 | 6 | |
| Median age, y (range) | 49.4 (16-60.9) | 41.9 (23-59.8) | 47.2 (18.3-60.9) | 46.4 (19.4-58.8) | .007 |
| Median WBC count, ×109/L (range) | 13.5 (0.2-369) | 13.9 (0.2-369) | 39.2 (0.2-345) | 30.1 (1.1-220) | .22 |
| Median PB blasts, % (range) | 27 (0-99) | 35 (0-98) | 55 (0-100) | 71 (1-96) | .01 |
| Median BM blasts, % (range) | 70 (0-100) | 72 (7-96) | 87 (2-100) | 88 (20-100) | .14 |
| Median LDH, U/L (range) | 362 (89-2371) | 422 (131-4566) | 559.5 (122-4091) | 755.5 (184-2992) | .007 |
WBC denotes white blood cell; PB, peripheral blood; BM, bone marrow; LDH, lactate dehydrogenase (normal value < 250 U/L); s-AML, secondary AML; and t-AML, therapy-associated AML.
Status on FLT3-ITD missing in 3 de novo AML and in 2 secondary AML after myelodysplastic syndrome.